WEQUAL-GLOBAL
17.11.2020 15:44:08 CET | Business Wire | Press release
Twenty-four female executives of leading EMEA companies have been identified as having the leadership traits for top level C-suite positions. The WeQual Awards (www.wequal.com/awards ) identify already successful senior women who are one level below C-suite, and are aimed at tackling the slow progress in appointing women to executive roles.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201117005907/en/
A quarter of the winners of previous UK and US WeQual Awards have since been promoted to the executive committees of FTSE and Fortune 500 companies.
“The glass-ceiling concept has been an issue for decades, and the drop-off is steepest just below the C-suite, so I launched WeQual to champion gender equality at the top,” says Katie Litchfield , founder and CEO of WeQual.
The EMEA finalists are from a wide range of sectors and companies, including Orange, Unilever, Schneider Electric, Bayer Consumer Health, ENGIE, KCB Group, Sodexo, Enel Group, L'Oréal, Mondi Group, Bureau Veritas, Standard Chartered, Veolia Environnement, Ericsson, Fresenius Medical Care, AkzoNobel, Ooredoo Qatar, Danone, Aryzta.
The 24 finalists were assessed against seven criteria: Leadership, Cognitive Ability, Integrity, Drive & Resilience, Equality, Knowledge of the Business, and Personal Development. All candidates were assessed blind with no name or company revealed in their application.
Eight executive interviewers will hold 30-minute interviews with the three finalists in their category before each choosing a category winner: Brand Innovation, Commercial Performance, Digital Impact, Finance, Head of Region, People Excellence, Strategy Development, and Transformational Leadership.
The finalists will be announced in December 2020.
Among supporters of the awards are Ann Cairns, Executive Chair of Mastercard and Global Chair of the gender equality campaign group ‘30% Club’; Sir Ian Cheshire, Chairman of Barclays; Dame Inga Beale; and Ron Kalifa OBE of Network International. They are part of a roster of well-known C-suite executives who will now choose eight category winners.
Sir Ian Cheshire says: "These awards are among the first to target women at this level. We believe building awareness of these talented people, as well as connecting them to each other, is an important step in improving diversity at top levels of business.”
This senior group of 24 executives will become members of the WeQual Club and join the existing 72 senior FTSE and Fortune 500 female executives.
(Ends)
Notes to editors
Methodology: The eight assessment questions were developed from a research-based meta-analysis of the factors and characteristics that mark leaders as different from non-leaders (Kirkpatrick and Locke, 1991). They were designed to help the women best describe how they deliver on leadership characteristics and how they are seen by others as a leader, and indeed engage people who see them as fit to lead.
About WeQual
WeQual's mission is to make businesses more inclusive by identifying exceptional women executives and address the gender imbalance across the world's Executive Committees. Katie Litchfield, founder and CEO of WeQual Awards, devised the new platform which calls for women senior executives to build their case as to why they are deserving to be appointed to the Executive Committee.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201117005907/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
The Estée Lauder Companies Appoints Madeleine Boyd as Senior Vice President, Global Brand Communications16.7.2026 22:22:00 CEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Madeleine Boyd as Senior Vice President, Global Brand Communications, effective July 20, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716738393/en/ Photo by Esteban La Tessa As part of the company’s continued efforts to strengthen how its brands better connect with consumers, Ms. Boyd will establish and lead a newly integrated Global Brand Communications team. In this role, she will ensure the company’s diverse portfolio is anchored by a cohesive enterprise communications strategy, while accelerating bold, consumer-first storytelling that drives earned media, cultural relevance, and brand desirability. She will also strengthen creator engagement, helping the company’s brands gain attention where culture is being shaped. Ms. Boyd brings extensive experience spanning brand strategy, communications, consumer engagement, and cultural insight
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom